Bluejay Diagnostics, Inc. (NASDAQ:BJDX) Short Interest Update

Bluejay Diagnostics, Inc. (NASDAQ:BJDX) was the target of a large drop in short interest in January. As of January 15th, there was short interest totaling 16,265 shares, a drop of 71.7% from the December 31st total of 57,446 shares. Approximately 0.9% of the company’s stock are sold short. Based on an average daily volume of 106,459 shares, the short-interest ratio is presently 0.2 days. Based on an average daily volume of 106,459 shares, the short-interest ratio is presently 0.2 days. Approximately 0.9% of the company’s stock are sold short.

Analyst Ratings Changes

A number of research analysts have recently issued reports on the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Bluejay Diagnostics in a report on Monday, December 29th. Wall Street Zen upgraded shares of Bluejay Diagnostics to a “sell” rating in a research note on Saturday, November 1st. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, the company currently has an average rating of “Sell”.

Bluejay Diagnostics Price Performance

Shares of BJDX opened at $3.44 on Friday. The firm has a market capitalization of $6.23 million, a P/E ratio of -0.03 and a beta of 0.65. Bluejay Diagnostics has a one year low of $2.51 and a one year high of $40.80. The business has a fifty day moving average of $3.60 and a 200 day moving average of $5.75.

Bluejay Diagnostics (NASDAQ:BJDX) last announced its earnings results on Friday, November 7th. The company reported ($4.04) earnings per share (EPS) for the quarter.

Bluejay Diagnostics Company Profile

Bluejay Diagnostics, Inc (NASDAQ: BJDX) is a molecular diagnostics company focused on developing saliva-based tests for autoimmune and gastrointestinal conditions. The company’s lead diagnostic product is designed to detect tissue transglutaminase (tTG) antibodies in patient saliva samples, offering a noninvasive, point-of-care alternative to traditional blood draws and endoscopic procedures.

Leveraging a proprietary immunoassay platform, Bluejay’s technology aims to streamline the detection and monitoring of celiac disease by providing rapid results outside of a conventional laboratory setting.